Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids

Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids

The value of lipid nanoparticles (LNPs) for delivery of messenger RNA (mRNA) was demonstrated by the coronavirus disease 2019 (COVID-19) mRNA vaccines, but the ability to use LNPs to deliver plasmid DNA (pDNA) would provide additional advantages, such as longer-term expression and availability of promoter sequences. However, pDNA-LNPs face substantial challenges, such as toxicity and low delivery efficiency. Here we show that pDNA-LNPs induce ac…

Wistar Institute Reveals Breakthrough in DNA-LNP Vaccine Technology

PHILADELPHIA, PA — A new study led by scientists at The Wistar Institute, in collaboration with the University of Pennsylvania Perelman School of Medicine and INOVIO, has unveiled advancements in next-generation vaccination technology. Published in Cell Reports Medicine, the research highlights how lipid nanoparticle (LNP)-formulated plasmid DNA (DNA-LNP) can enhance vaccine delivery and immune response. The study, led by Wistar doctoral student…

Scientists Demonstrate Pre-clinical Proof of Concept for Next-Gen DNA Delivery Technology

PRESS RELEASE CONTACT: Darien Sutton 215-870-2048  |  dsutton@wistar.org Findings show potential for new lipid-based delivery  formulations as a platform technology for immunization PHILADELPHIA — (March 21, 2025) — Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pennsylvania Perelman School of Medicine and at the Pennsylvania-h…